enGene Therapeutics Inc.

enGene Holdings Inc. is a clinical-stage biotechnology company focused on mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with an initial focus on non-muscle invasive bladder cancer (NMIBC) ⁶. The company is developing non-viral genetic medicines utilizing its proprietary dually derived chitosan, or "DDX", gene delivery platform, which enables localized delivery of complex genetic cargos directly to mucosal tissues and other organs ⁷. The company believes its DDX platform has the potential to be a next-generation platform for genetic medicine, overcoming historical challenges such as immunogenicity, safety concerns, limited efficacy, high cost of goods, lack of commercially viable manufacturing technology, systemic toxicity, and administration difficulties ¹³.

The core business model revolves around the research, development, and potential commercialization of novel genetic medicines. The company generates revenue primarily through third-party investments in its debt and equity instruments, as it has not yet generated any product revenue ¹⁹. Its primary customer segments, if products are approved, would be patients with high unmet medical needs, initially focusing on those with BCG-unresponsive NMIBC with carcinoma in situ (CIS) ⁹. The company plans to retain commercial rights for its lead product candidate, detalimogene, in the United States and commercialize it independently, while selectively partnering outside the United States ¹⁵.

The company's lead product candidate is detalimogene voraplasmid, formerly known as EG-70. Detalimogene is a therapy designed to promote a pro-inflammatory, anti-tumor microenvironment in the bladder urothelium, aiming to enable the immune system to clear tumors and resist recurrence ⁸. It consists of a small plasmid DNA encapsulated in DDX nanoparticles, further coated with a modified polyethylene glycol (PEG) polymer to enhance diffusion through the bladder wall ¹⁶. The plasmid DNA encodes for single-chain interleukin-12 (IL-12) protein and two non-coding RNAs, eRNA11a and VA1, which activate the retinoic acid-inducible gene I (RIG-I) pathway, stimulating both innate and adaptive immunity ¹⁷. Detalimogene is currently being studied in a combined Phase 1/2 open-label trial called LEGEND (ClinicalTrials.gov identifier NCT04752722) ¹⁰.

The LEGEND study's Phase 2 portion includes three cohorts: Cohort 1, a pivotal cohort, enrolled 125 patients with high-risk BCG-unresponsive NMIBC with CIS, with or without concomitant papillary disease ¹¹. Cohort 2 is evaluating detalimogene in patients with high-risk BCG-naïve NMIBC with CIS (Cohort 2a, with 30 enrolled patients as of November 11, 2025) and high-risk BCG-exposed NMIBC with CIS (Cohort 2b, with 45 enrolled patients as of November 11, 2025) ¹². Cohort 3 is evaluating detalimogene in patients with high-risk BCG-unresponsive NMIBC who have papillary disease only (36 enrolled patients as of November 11, 2025) ¹². Preclinical research is also focused on expanding detalimogene to other cancer indications and applying the DDX platform to other unmet medical needs ¹⁴.

For the fiscal year ended October 31, 2025, the company reported net losses of $117.3 million ²⁰, compared to $55.1 million for the fiscal year ended October 31, 2024 ²⁰. As of October 31, 2025, the accumulated deficit was $372.0 million ²¹. The company had $50.2 million in cash and cash equivalents and $152.1 million in marketable securities as of October 31, 2025 ²². No product revenue has been generated to date ¹⁹.

Preliminary data from the pivotal Cohort 1 of the LEGEND study, with a data cut-off of October 24, 2025, showed that among Post-Protocol Amendment Patients, 62% of patients remained in complete response (CR) at six months after treatment initiation ¹⁸. All evaluable patients at nine months in this subpopulation also demonstrated continued CR ¹⁸. The overall tolerability profile was favorable, with 42% of the 125 patients assessed for safety in Cohort 1 experiencing at least one treatment-related adverse event (TRAE), primarily Grades 1/2 in severity, and only three patients (2.4%) experiencing Grade 3 TRAEs ¹⁸. No Grade 4 or Grade 5 TRAEs were reported ¹⁸.

Significant operational developments include the completion of enrollment for Cohort 1 of the LEGEND study with 125 patients ¹¹. The primary endpoint for Cohort 1 was changed in the second half of 2025 to the percentage of patients with CR at any time, based on cystoscopic exam, urine cytology, and biopsies, aligning with recently approved products for BCG-unresponsive NMIBC ¹⁸. A protocol amendment was implemented in the fourth quarter of 2024 to better align LEGEND with the standard of care for NMIBC with CIS, modifying patient evaluation and treatment at key points during the trial ¹⁸. The company also deprioritized preclinical development of another product candidate, EG-i08 for cystic fibrosis, in June 2024, to prioritize exploring potential bladder cancer indications for detalimogene ²³.

The company plans to file a Biologics License Application (BLA) with the FDA in the second half of 2026 for approval to market detalimogene in the United States as a monotherapy for BCG-unresponsive NMIBC with CIS, contingent on supportive Phase 2 results from the pivotal cohort of the LEGEND study ²⁴. If marketing approval is granted, the company intends to commercialize detalimogene independently in the United States, establishing a U.S.-focused sales and marketing organization to coordinate with high-prescribing community urology centers ²⁵. The commercialization strategy also includes establishing a specialty urologic medical science liaison team to support scientific exchange and education about detalimogene ²⁶.

Major growth vectors include exploring additional clinical applications of detalimogene within high-risk NMIBC, beyond the BCG-unresponsive population with CIS. The Phase 2 LEGEND trial is assessing detalimogene in BCG-Naïve NMIBC with CIS (Cohort 2a), BCG-exposed NMIBC with CIS (Cohort 2b), and BCG-unresponsive, papillary-only NMIBC (Cohort 3) ²⁷. The company also believes detalimogene has potential as a treatment for other forms and stages of bladder cancer, including muscle invasive disease and earlier stage low- and intermediate-risk NMIBC populations, supported by preclinical data suggesting it drives profound and durable anti-tumor immunity and resistance to tumor re-challenge ²⁸.

Another significant growth vector is applying the proprietary DDX platform to other mucosal tissues. The company believes its clinical data and preclinical proof-of-concept studies demonstrate the value and breadth of the DDX platform for delivering genetic medicines to mucosal tissues, including the urinary tract, lung, and gastrointestinal tract ²⁹. This is expected to enable the development of new agents beyond detalimogene, unlocking better outcomes for historically difficult-to-treat conditions ³⁰. The DDX platform offers payload flexibility, including the ability to deliver multiple genes (DNA and RNA) in a single drug product, without integration into the host's genomic DNA ³¹.

Operationally, the company has developed manufacturing processes for DDX and detalimogene that it believes are robust, cost-effective, and scalable, and are in accordance with current Good Manufacturing Practice (cGMP) and quality system regulations ³². These processes involve incorporating plasmid DNA with the DDX carrier using commercially available equipment and are patent-protected with proprietary know-how ³³. The company has scaled up its manufacturing processes to a level believed to meet the needs of a potential commercial launch for detalimogene ³⁴. It relies on qualified external contract manufacturers (CMOs) for production and custom manufactures the PEG-b-PLE excipient and pDNA drug substance from qualified cGMP manufacturers in the European Union ³⁵. The company plans to enter into long-term commercial supply agreements with selected qualified CMOs if marketing approval is granted in the United States ³⁶.

Planned capital allocation includes significant investments in continued research and development of detalimogene and other new product candidates and genetic medicines ³⁷. The company expects to incur substantial costs for commercialization, as well as research and development and other expenses to discover, develop, and market additional potential products ³⁸. As of October 31, 2025, the company had $50.2 million in cash and cash equivalents and $152.1 million in marketable securities ²². The company will require additional capital to complete clinical development of its current programs ³⁹, and expects to finance future cash needs through public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, royalty revenues, sales or monetization of future revenue streams, marketing or distribution arrangements, or other strategic transactions ⁴⁰.

The company explicitly flags several structural headwinds and execution risks. It depends heavily on the success of detalimogene, its only product candidate in clinical development, and its clinical trial may not be successful, potentially harming the business ⁴¹. The company has incurred net losses since inception and anticipates continued losses, requiring additional capital to fund operations ⁴². Estimates of market sizes and forecasts for detalimogene and other product candidates are based on assumptions and may prove inaccurate, leading to a smaller actual market and adversely affecting business ⁴³. The company also faces significant competition from other biotechnology and pharmaceutical companies, which may develop and commercialize products more effectively or before enGene ⁴⁴. Detalimogene and the DDX platform are based on novel, unproven technologies, making development time and cost, and regulatory approval, difficult to predict ⁴⁵. Manufacturing detalimogene is complex, and scaling capabilities may encounter difficulties, potentially constraining, delaying, or stopping supply for clinical trials or commercialization, or preventing a commercially viable cost structure ⁴⁶.

Geographic, regulatory, and macro factors identified as constraints include extensive regulation by various U.S. federal and state agencies and non-U.S. regulatory bodies, with compliance resulting in unanticipated expenses or limiting product offerings ⁴⁷. Regulatory approval is a lengthy, expensive, and unpredictable process, with no assurance of approval or timely approval ⁴⁸. Ongoing healthcare legislative and regulatory reform measures, including the U.S. federal government's determination that any product candidates are "essential" biologic medicines, may adversely affect the business ⁴⁹. Global economic uncertainty, changes in geopolitical conditions, and weakening product demand due to political instability, trade agreements, and disputes (such as armed conflicts between Russia and Ukraine and in the Middle East) and other macroeconomic factors could adversely affect the business ⁵⁰.

The company faces material risks including heavy dependence on the success of its lead product candidate, detalimogene, which is currently in clinical trials and may not be successfully developed, approved, or commercialized, leading to material harm to the business ⁴¹. Significant investments in research and development for detalimogene and other product candidates may not be successful, limiting future profitability ³⁷. The company has incurred net losses in every year since inception, with net losses of $117.3 million for the fiscal year ended October 31, 2025, and $55.1 million for the fiscal year ended October 31, 2024, and an accumulated deficit of $372.0 million as of October 31, 2025 [20, 21]. It will need to raise additional capital to fund operations, and failure to obtain necessary financing will prevent completion of development and commercialization ³⁹. The estimates of market sizes and forecasts of market growth for detalimogene and other product candidates are based on assumptions and may prove inaccurate, adversely affecting business and results of operations ⁴³. The company faces significant competition from other biotechnology and pharmaceutical companies, which may develop or commercialize products more successfully ⁴⁴. Detalimogene and the genetic medicine platform are based on novel, unproven technologies, making development time, cost, and regulatory approval unpredictable ⁴⁵. Interim data from clinical trials are subject to change as more patient data become available and are subject to audit and verification, which could result in material changes in final data ⁵¹. Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities ⁵². The company has not completed later-stage or pivotal clinical trials or submitted a BLA as an organization, and may be unable to do so in a timely manner or at all ⁵³. Use of novel genetic medicine platform and product candidates could result in harmful side effects, adverse events, or other safety risks, leading to delays, suspensions, or discontinuation of clinical trials, or limiting commercial potential ⁵⁴. If approved, products may fail to achieve market acceptance by physicians, patients, and third-party payors ⁵⁵. Negative developments in the genetic medicine field could damage public perception of detalimogene and other product candidates ⁵⁶. The company relies on third parties for manufacturing, development, and testing, increasing the risk of insufficient quantities, delays, or unacceptable costs ⁴⁶. Detalimogene is complex to manufacture, and scaling manufacturing capabilities may encounter difficulties, potentially constraining, delaying, or stopping supply, or preventing a commercially viable cost structure ⁴⁶. Changes in manufacturing or formulation may result in additional costs or delays ⁵⁷. Detalimogene is complex to analyze, and difficulties in product release testing, particularly bioassay potency testing, could delay or stop supply or prevent a commercially viable cost structure ⁵⁸. The market opportunities for detalimogene may be limited to a small group of patients, and estimates of target patient populations may be inaccurate ⁵⁹. The company depends on its executive team and key personnel, and loss or inability to attract highly skilled employees could harm the business ⁶⁰. Research and development initiatives, manufacturing processes, and business depend on attracting and retaining highly skilled scientists and specialized individuals, which may be difficult due to competition ⁶¹. The company is vulnerable to natural disasters, political crises, acts of terrorism, epidemics, and other catastrophic events, and its business continuity and disaster recovery plans may be inadequate ⁶². Nearly all aspects of the company's activity and products are subject to extensive regulation by various U.S. federal and state agencies and non-U.S. regulatory bodies, and compliance could result in unanticipated expenses or limit product offerings ⁴⁷. Regulatory approval is a lengthy, expensive, and unpredictable process, with no assurance of approval or timely approval ⁴⁸. The FDA's Fast Track and RMAT designations, and participation in the CDRP Program, do not guarantee faster development, review, or approval, or increased likelihood of regulatory approval ⁶³. Ongoing regulatory obligations, reporting requirements, and continued regulatory review post-approval may result in significant additional expenses, with substantial penalties for non-compliance or unanticipated problems ⁶⁴. Contract manufacturers are subject to significant regulation, and their facilities may not meet or continue to meet regulatory requirements or may have limited capacity ⁶⁵. Ongoing healthcare legislative and regulatory reform measures, including the Inflation Reduction Act of 2022 (IRA), may adversely affect the business and results of operations, potentially reducing prices and reimbursement for products ⁴⁹. Product candidates may become subject to unfavorable or unprofitable third-party coverage and reimbursement practices, as well as pricing regulations ⁶⁶. Drug marketing, price controls, and reimbursement regulations may materially affect the ability to market and receive coverage for product candidates in non-U.S. jurisdictions ⁶⁷. Guidelines and recommendations published by various organizations, such as ICER, may impact the use or reimbursement of detalimogene ⁶⁸. The company is subject to stringent privacy and information security laws, regulations, policies, and contractual obligations, and changes or non-compliance could adversely affect the business ⁶⁹. Cyber-attacks or other failures in IT systems could result in information theft, data corruption, and significant disruption ⁷⁰. Inadequate funding for, or changes in leadership at, or disruptions at the FDA, SEC, and other government agencies could hinder their ability to perform normal functions, negatively impacting the business ⁷¹. Employees, contractors, and partners may engage in misconduct or improper activities, including noncompliance with regulatory standards ⁷². The company is subject to U.S. and non-U.S. anti-corruption, anti-money laundering, export control, sanctions, and other trade laws, with serious consequences for violations ⁷³. The company's ability to use net operating loss carry-forwards and certain other tax attributes may be limited ⁷⁴. There is a significant risk that the company may continue to be a passive foreign investment company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. Holders of its Common Shares or Warrants ⁷⁵.

Management emphasizes its focus on advancing detalimogene through late-stage clinical development and seeking regulatory marketing approval in the United States, with a plan to file a Biologics License Application (BLA) with the FDA in the second half of 2026 for BCG-unresponsive NMIBC with CIS ²⁴. A key strategic priority is to build a fully integrated company by independently commercializing approved products in indications and key geographies where the value of detalimogene can be maximized, specifically retaining commercial rights in the United States while selectively partnering outside the U.S. ¹⁵. Management also highlights exploring additional clinical applications of detalimogene within high-risk NMIBC, including BCG-Naïve, BCG-exposed, and papillary-only BCG-unresponsive NMIBC, and believes in the potential to develop detalimogene for other forms and stages of bladder cancer [27, 28]. A further strategic priority is to apply the proprietary DDX platform to other mucosal tissues, leveraging its clinical data and preclinical proof-of-concept studies to develop new agents beyond detalimogene ²⁹.